Abstract: SA-PO0771
Early Insights into Characteristics and Treatment Patterns of US Patients (Pts) with IgAN Who Were Prescribed Iptacopan: The APPRISE-IgAN Data Platform
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Narayanan, Mohanram, Baylor Scott & White Health, Temple, Texas, United States
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Khairnar, Rahul, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Tang, Jackson, Asclepius Analytics, New York, New York, United States
- Buchan, Claire, Asclepius Analytics, New York, New York, United States
- Buchan, Tayler, Asclepius Analytics, New York, New York, United States
- Gargano, Peter, Onco360, New York, New York, United States
- Nusser, Hayley, Biologics Inc, Cary, North Carolina, United States
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Srinivas, Titte, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Canetta, Pietro A., Columbia University, New York, New York, United States
Background
Iptacopan, an alternative complement pathway factor B inhibitor, received accelerated FDA approval to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. A Patient Platform for Real-world data on Iptacopan in the United StatEs for pts with IgAN (APPRISE-IgAN) is a data platform capturing real-world data on US pts with IgAN prescribed iptacopan. This interim analysis provides early insights into characteristics and treatment patterns of pts enrolled in APPRISE-IgAN to date.
Methods
APPRISE-IgAN includes retrospective, longitudinal, deidentified pt-level data from adults with IgAN who are prescribed iptacopan and give written consent for enrollment. This analysis included pts enrolled from Aug 2024 to May 2025. Treatment information was sourced from specialty pharmacy records, and pt characteristics and treatment patterns from medical charts. Therapy duration was from date of iptacopan initiation (index) to first instance of discontinuation/data cutoff. Treatment adherence was assessed by medication possession ratio (MPR; total days’ supply to days covered) and proportion of days covered (PDC; ratio of days with supply to days covered).
Results
Of 74 pts invited in the specified period, 17 enrolled in APPRISE-IgAN. At index, mean ± SD pt age was 44.7 ± 12.7 years; 47% were male. Most (88%) had commercial insurance and 12% had Medicare. All pts had history of treatment for IgAN before starting iptacopan; delayed-release budesonide (71%), sodium-glucose cotransporter-2 inhibitors (71%), and corticosteroids (41%) were most common. By data cutoff, no pts discontinued iptacopan; median (interquartile range [IQR]) iptacopan treatment duration was 4.8 (3.2–5.5) months. Median (IQR) number of iptacopan pharmacy fills was 5.0 (4.0–6.0). Median (IQR) MPR and PDC were 106% (101–111%) and 96% (93–99%), respectively.
Conclusion
This interim analysis highlights characteristics and treatment patterns of pts with IgAN receiving iptacopan. Recruitment for APPRISE-IgAN and collection of data for additional pts, clinical outcomes, and longer follow-up times are ongoing and will provide further valuable insights on this pt population over time.
Funding
- Commercial Support – Novartis Pharmaceuticals Corporation